tubeshowcase●1,672,197 videos♡ My collection 0
← News

News09:50

Why Enliven is this analyst's top biotech stock pick

Yahoo Finance ↗

From the creator

Salim Syed, Mizuho Americas managing director and senior analyst, joins the latest edition of Good Buy or Goodbye to discuss his top and bottom picks in the pharmaceutical industry. Syed points to Enliven Therapeutics (ELVN) as his top pick, believing that its drugs in development are promising. He specifically highlights ELVN-001, which is for a type of blood cancer called CML. He explains, "What you would want with these particular products is that they don't have any sort of cardiovascular toxicity, and they just put out six-month or 24-week safety data, and it looked pretty clean." He notes that CML has been growing and that patients are living longer, meaning that they are on drugs for a longer time. "It's now a $14 billion global market. We think it's pretty feasible that a product like ELVN-001, even when you're talking about not getting the first line share, the drug that's prescribed first, but even the second drug after the first line, something in the order of 1 to 2 billion," he tells Yahoo Finance. Syed continues, "It's like, well what sort of multiple would you like to put right on a $1-$2 billion revenue line? The stock is currently trading at a billion and change market cap. We think it's easy to start looking at this as more of a $2 billion, $3 billion story." However, one potential risk he highlights is that the drug is still in Phase I of trials, and if all goes to plan, it could hit the market in 2028. On the other hand, Syed is bearish on Amgen (AMGN), be

Published 2024-10-18 · Watch on YouTube ↗
Availability and playback restrictions are controlled by the original channel.

Keep exploring News